Abstract: The invention is directed to an isolated genomic polynucleotide fragment that encodes human soluble (cytosolic) aminopeptidase P, vectors and hosts containing the fragment and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human soluble aminopeptidase P and to diagnose, treat, prevent and/or ameliorate a pathological disorder.

Abstract: The present invention provides a cell-free protein synthesis method characterized by a cell-free protein synthesis reaction solution that is weakly reducing and suitable for protein folding, performing a weakly reducing synthesis reaction, and preferably performing a translation reaction with the further addition of a substance catalyzing a disulfide bond exchange reaction at the beginning of the translation reaction. This method allows for proper formation of intramolecular disulfide bonds in the protein and efficiently provides protein having substantially the same function as the original protein. Specifically, it provides antibody protein that binds specifically to an antigen.

Abstract: The present invention relates to use of an anti-staling GH-61 polypeptide for preparing an edible product.

Abstract: Methods are provided for intein mediated trans-splicing of immobilized polypeptides and for producing cyclic polypeptides in vivo or in vitro.

Abstract: The use of a biologically active complex of ?-lactalbumin, selected from HAMLET (human ?-lactalbumin made lethal to tumour cells) or a biologically active modification thereof, or a biologically active fragment of either of these, in the preparation of a medicament for use in the treatment of papilloma, such as cutaneous papillomas.

Abstract: Caulobacter optimized for use in expression of heterologous peptides as part of a hybrid Caulobacter S-layer protein are provided as well as methods for producing such Caulobacter. Caulobacter of this invention are deficient in a native Caulobacter protease that cleaves hybrid S-layer proteins. Also provided are Caulobacter libraries and methods for sorting such libraries using cell sorting technology such as FACS.

Abstract: Provided are crystals and structure coordinates relating to FMS-like tyrosine kinase 3 and its various uses.

Abstract: Described is a nucleic acid coding for a protein called “cyplasin” that shows a preferential toxicity to autonomously growing mammalian cells. Cell death induced by this protein differs from both apoptosis and necrosis. An intracellular cell death which occurs when recombinantly preparing cyplasin in cell cultures can be avoided by removal of the secretion signal in the cyplasin sequence. This modification makes it possible to express the cyplasin in a mammalian cell culture which is preferable with regard to the glycosylation pattern of the obtained protein. Thus, the present invention also relates to a method of recombinantly producing a protein in eukaryotic cells, preferably mammalian cells, which is cytotoxic for said cells when applied externally.

Abstract: Methods for making glycoproteins, both in vitro and in vivo, are provided. One method involves incorporating an unnatural amino acid into a protein and attaching one or more saccharide moieties to the unnatural amino acid. Another method involves incorporating an unnatural amino acid that includes a saccharide moiety into a protein. Proteins made by both methods can be further modified with additional sugars.

Abstract: The present invention relates to methods for the diagnosis and treatment of a urological disorder or urological disorders. Specifically, the present invention identifies the differential expression of Carboxypeptidase Z, identified as “8263” gene in tissues relating to urological disorder, relative to their expression in normal, or non-urological disorder disease states, and/or in response to manipulations relevant to a urological disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various urological diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a urological disorder or urological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of urological disorders.

Abstract: This invention relates to a novel PTH gene. The invention further relates to methods of screening, diagnosis and development of therapies for bone related disorders.

Abstract: Described are methods of treating and preventing conditions associated with a loss of elastic fibers. Also provided herein are methods of screening for agents useful in treating such conditions, and animal models of conditions associated with a loss of elastic fibers.

Abstract: The present invention discloses a method for producing foods and/or beverage having improved taste and/or flavour, comprising reacting a microbial aminopeptidase on a protein material optionally under the co-existence of a protease, wherein said aminopeptidase has the properties of: (a) having an activity of catalyzing the reaction of specifically releasing a glutamic acid and an aspartic acid from the N-terminal of a peptide and/or a protein; (b) having 50% or more activity at pH6.0-9.0 as compared with the activity at the optimum pH; (c) having 40% or more activity after heating at 25-60° C., pH7.5 for 30 minutes as compared with the activity of the non-heated enzyme; (d) having a molecular weight of about 40-60 kD as measured by SDS-PAGE and about 300-480 kD as measured by native-PAGE; (e) having a hydrolyzing activity of the aminopeptidase toward Glu-Glu dipeptide is 5 U/mg or more, preferably 10 U/mg or more.

Abstract: A mammalian homology of Drosophila Disabled protein has been identified and cloned. In particular, the murine homolog designated mDab1 has been cloned and expressed. mDab1, when tyrosine phosphorylated, binds to the SH2 domain of Src, Abl and Fyn. Antibodies specific for mDab1 are provided as are methods for the screening of agents for their ability to modulate mDab1 activity. Methods for diagnosing Disabled protein associated disease are also provided.

Abstract: Provided are crystals relating to human Glucocorticoid Receptor and its various uses.

Abstract: The present invention pertains to novel strains of lactic acid bacteria capable of reducing an individual's tendency to react allergic against a variety of different allergens. In particular, the present invention relates to recombinant strains of lactic acid bacteria that express surface polypeptides which include peptides or antibody fragments acting as mimic for at least a part of the Fc region of IgE-molecules. The invention also pertains to food or pharmaceutical compositions containing said micro-organisms or active fractions thereof.